EXHIBIT 1Statement on Schedule 13d • October 13th, 2005 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.01 par value, of Biocryst Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13d • November 9th, 2011 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Synageva BioPharma Corp, Inc. and suchother amendments as may be filed by them hereafter, are being filed with the Securities and Exchange Commission on behalf of each of them.
ContractStatement on Schedule 13d • August 30th, 2005 • Comprehensive Associates LLC • Services-misc health & allied services, nec
The undersigned agree that the Statement on Schedule 13D to which this Agreement is attached is filed on behalf of each one of them.
AGREEMENTStatement on Schedule 13d • July 9th, 2004 • Neurogen Corp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.025 par value, of Neurogen Corporation is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13d • June 9th, 2011 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
